Tricida, Inc. (TCDA) Stock Analysis
DELISTED 2023
What happened to Tricida, Inc. (TCDA) stock?
Tricida, Inc. (TCDA) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tricida, Inc. (TCDA) trades at $0.108. Tricida, Inc. is a biotechnology company focused on developing veverimer, a treatment for metabolic acidosis in chronic kidney disease patients. Market cap: $5.95M, Sector: Healthcare.
Last analyzed: May 7, 2026Analyst Coverage for TCDA: TCDA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TCDA against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
TCDA: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Tricida, Inc. (TCDA) Healthcare & Pipeline Overview
Tricida, Inc. specializes in the development of veverimer, an innovative non-absorbed polymer aimed at treating metabolic acidosis in chronic kidney disease patients, positioning itself as a key player in the biotechnology sector focused on renal health.
What Is the Investment Thesis for TCDA?
Tricida, Inc. presents a unique investment thesis centered on its proprietary product, veverimer, which has completed Phase III trials targeting metabolic acidosis in CKD patients. The growing prevalence of CKD, projected to affect over 14% of the U.S. population, underscores the significant market opportunity for veverimer. The company's focus on a non-absorbed polymer therapy distinguishes it from traditional treatments, potentially leading to a strong market position upon commercialization. Additionally, Tricida's strategic initiatives to secure partnerships and navigate regulatory pathways effectively will be crucial in driving future revenue growth. However, investors should be mindful of potential risks associated with clinical trial outcomes and market competition as the company moves towards product launch.
Based on FMP financials and quantitative analysis
TCDA Key Highlights
Market capitalization of $5.95M reflects the early-stage nature of the company and its current developmental focus.
- No dividend yield as the company reinvests in research and development to advance veverimer.
- Completion of Phase III trials represents a critical milestone, positioning Tricida for potential market entry.
- A workforce of 57 employees indicates a lean operational structure focused on specialized drug development.
- The company operates in a growing market, with chronic kidney disease affecting a significant portion of the population.
Who Are TCDA's Competitors?
TCDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| RGEN Repligen Corporation | $180.29 | +2.23% | $10.2B | 81 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TCDA's Key Strengths?
Innovative product targeting a specific and underserved patient population.
- Completion of Phase III trials enhances credibility and market readiness.
- Strong leadership with expertise in biotechnology and pharmaceuticals.
What Are TCDA's Weaknesses?
Limited financial resources reflected in a low market capitalization.
- Dependency on successful regulatory approval for veverimer.
- Small workforce may limit operational capacity and scalability.
What Could Drive TCDA Stock Higher?
Regulatory submission for veverimer expected in late 2026, which could lead to market approval.
- Phase III trial results have been completed, paving the way for commercialization efforts.
- Strategic partnerships may be pursued to enhance market entry and distribution capabilities.
What Are the Key Risks for TCDA?
Financial-distress signal — its Altman Z-Score of -16.65 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory approval risks associated with veverimer could impact market entry timelines.
- Competition from established pharmaceutical companies may affect market share.
- Clinical trial outcomes could influence investor confidence and stock performance.
What Are the Growth Opportunities for TCDA?
- Growth opportunity 1: The global chronic kidney disease market is projected to grow significantly, reaching $20 billion by 2027, driven by increasing prevalence rates and a growing aging population. Tricida's focus on veverimer positions it to capture a share of this expanding market, particularly as awareness of metabolic acidosis in CKD patients increases.
- Growth opportunity 2: Regulatory approval for veverimer could lead to rapid commercialization, with potential market entry as early as 2026. Successful launch and adoption of veverimer could significantly enhance Tricida's revenue streams and market presence.
- Growth opportunity 3: Expansion into international markets presents a substantial growth avenue, particularly in regions with high CKD prevalence and limited treatment options. Tricida may explore partnerships or collaborations to facilitate entry into these markets, enhancing its global footprint.
- Growth opportunity 4: The ongoing research into additional indications for veverimer beyond metabolic acidosis could unlock new revenue streams. By exploring its application in other related conditions, Tricida can diversify its product offerings and reduce dependency on a single therapeutic area.
- Growth opportunity 5: Strategic partnerships with larger pharmaceutical companies could accelerate development timelines and provide additional resources for commercialization. Collaborations could enhance Tricida's operational capabilities and expand its reach within the healthcare ecosystem.
What Are TCDA's Competitive Advantages?
- Proprietary formulation of veverimer provides a unique treatment option in the market.
- Strong focus on a niche therapeutic area with significant unmet medical need.
- Completion of Phase III trials enhances credibility and potential for market approval.
- Experienced leadership team with a track record in drug development.
- Lean operational structure allows for agile responses to market changes.
What Does TCDA Do?
Tricida, Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. The company operates as a pharmaceutical entity dedicated to the development and commercialization of veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients suffering from chronic kidney disease (CKD). Veverimer works by binding to excess acid in the gastrointestinal tract, effectively removing it from the body and thus addressing the acid-base imbalance that can occur in CKD patients. The completion of Phase III clinical trials signifies a critical milestone in the company’s journey, highlighting its commitment to bringing innovative solutions to market for patients with significant unmet medical needs. With a workforce of 57 employees, Tricida is poised to leverage its specialized knowledge in drug development and commercialization to navigate the complexities of the healthcare landscape. As the prevalence of chronic kidney disease continues to rise, Tricida's focus on this niche therapeutic area positions it strategically within the biotechnology sector, where it aims to deliver impactful treatments that enhance patient outcomes.
What Products and Services Does TCDA Offer?
- Develops veverimer, a treatment for metabolic acidosis in chronic kidney disease patients.
- Focuses on non-absorbed orally-administered polymer therapies.
- Conducts clinical trials to assess the efficacy and safety of its products.
- Aims to address significant unmet medical needs in renal health.
- Operates within the biotechnology sector, targeting innovative drug development.
- Seeks regulatory approval for its lead product to facilitate market entry.
How Does TCDA Make Money?
- Primarily generates revenue through the commercialization of veverimer upon regulatory approval.
- Focuses on research and development funding to advance clinical trials and product development.
- Engages in potential partnerships and collaborations to enhance resource capabilities.
- Utilizes a lean operational structure to maximize efficiency in drug development.
- Aims to capture market share in the growing chronic kidney disease treatment sector.
What Industry Does TCDA Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in drug development and increasing demand for innovative therapies. Chronic kidney disease is becoming a major public health concern, with the global market for CKD treatments expected to reach approximately $20 billion by 2027. Tricida, Inc. operates within this expanding market, focusing on a specialized treatment for metabolic acidosis, a common complication in CKD. The competitive landscape includes both established pharmaceutical companies and emerging biotech firms, but Tricida's unique approach to addressing metabolic acidosis positions it favorably among its peers.
Who Are TCDA's Key Customers?
- Patients suffering from chronic kidney disease.
- Healthcare providers and nephrologists prescribing treatments for CKD.
- Pharmaceutical partners for potential collaborations and distribution.
- Research institutions involved in clinical trials and studies.
- Payers and insurance companies covering CKD treatments.
Company Profile
Tricida, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Gerrit Klaerner. TCDA has traded publicly since 2018.
TCDA Valuation & Market Position
With a $5.95M market cap, Tricida, Inc. sits in the micro-cap segment of the market.
Financial Health
Tricida, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.65 places it in the distress zone, a signal of elevated financial risk.
TCDA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- Community sentiment has turned positive as discussions around Tricida's pipeline developments gain traction.
- Analysts are highlighting the company's innovative approach to treating metabolic diseases, which could position it well in a growing market.
- Recent partnerships and collaborations have sparked optimism about Tricida's ability to enhance its product offerings and market reach.
Bear Case
- Concerns about the company's cash runway have surfaced, raising questions about its ability to sustain operations without additional funding.
- Social media sentiment reflects skepticism regarding the timeline for product approvals, which could hinder growth prospects.
- Recent market developments have created uncertainty around competitive pressures in the metabolic disease space, potentially impacting Tricida's market position.
- Bearish community views emphasize the risks associated with clinical trial outcomes, which could significantly affect the stock's trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TCDA Latest News
No recent news available for TCDA.
Leadership: Gerrit Klaerner
CEO
Gerrit Klaerner has extensive experience in the biotechnology sector, having held various leadership roles in drug development and commercialization. He holds a degree in Biomedical Engineering and has worked in both startup and established pharmaceutical environments, contributing to the advancement of several therapeutic candidates.
Track Record: Under Klaerner's leadership, Tricida has successfully navigated the complexities of clinical trials, culminating in the completion of Phase III trials for veverimer. His strategic vision has positioned the company for potential market entry and growth in the renal health sector.
Common Questions About TCDA (Healthcare)
What happened to Tricida, Inc. (TCDA) stock?
Tricida, Inc. (TCDA) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
Can I still buy TCDA shares?
No. TCDA stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for TCDA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TCDA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Tricida, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Tricida, Inc. do?
Tricida, Inc. is a biotechnology company focused on developing veverimer, a treatment for metabolic acidosis in chronic kidney disease patients. The company aims to address significant unmet medical needs through innovative therapies that remove excess acid from the gastrointestinal tract, thereby improving patient outcomes.
What do analysts say about TCDA stock?
Analysts generally view TCDA as a high-risk, high-reward investment given its focus on a niche therapeutic area. Key valuation metrics include its market capitalization of $5.95M and the potential for significant revenue growth upon successful commercialization of veverimer, which is currently in the regulatory phase.
What are the main risks for TCDA?
The main risks for Tricida, Inc. include regulatory approval uncertainties for veverimer, which could delay market entry and impact stock performance. Additionally, competition from established pharmaceutical companies poses a threat to market share, while clinical trial outcomes will be critical in determining investor confidence and future funding opportunities.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on the latest available data as of May 2026.